|1.||Ito, S: 4 articles (11/2008 - 09/2001)|
|2.||Wakamatsu, K: 4 articles (11/2008 - 09/2001)|
|3.||Kågedal, B: 4 articles (06/2002 - 01/2000)|
|4.||Wakamatsu, Kazumasa: 3 articles (03/2011 - 08/2003)|
|5.||Ito, Shosuke: 3 articles (03/2011 - 08/2003)|
|6.||Arstrand, K: 3 articles (06/2002 - 07/2000)|
|7.||Paquet, Philippe: 2 articles (04/2011 - 07/2007)|
|8.||Crommen, Jacques: 2 articles (04/2011 - 07/2007)|
|9.||Fillet, Marianne: 2 articles (04/2011 - 07/2007)|
|10.||Chiap, Patrice: 2 articles (04/2011 - 07/2007)|
|1.||Melanoma (Melanoma, Malignant)
04/15/2011 - "Pre-study and in-study validation of a SPE-LC-MS-MS method for the determination of 5-S-cysteinyldopa, a melanoma biomarker, in human plasma."
01/01/2002 - "The aim of the present study was to compare the prognostic values of serum 5-S-Cysteinyldopa, S-100B and LDH concentrations in Stage III-IV melanoma patients. "
10/01/1997 - "Our study suggests that of the three biochemical tumour markers, S100B and to a lesser extent 5-S-cysteinyldopa have the greatest potential to be used as predictors of survival prognosis in patients with malignant melanoma."
08/01/2010 - "Possible case for false-positive reaction in serum 5-S-cysteinyldopa levels in a patient with malignant melanoma by ingestion of Agaricus blazei Murrill extract."
04/01/2009 - "Treatment of primary melanoma of the lung monitored by 5-S-cysteinyldopa levels."
|2.||Neoplasm Metastasis (Metastasis)
12/01/1980 - "In the case of small and circumscribed metastases which could be eliminated by surgical treatment, the excretion of 5-S-Cysteinyldopa remained normal. "
10/01/2005 - "No local relapse, distant metastasis or re-elevation of plasma 5-S-cysteinyldopa was identified during nine months of follow-up. "
02/15/1983 - "If the complaints and the pathologic values are early symptoms and signs of generalized metastases being clinically not yet manifest, the excretion of 5-S-cysteinyldopa in the urine is often increased. "
12/01/1980 - "In the remaining cases, the increase of 5-S-Cysteinyldopa coincided with the manifestation of metastases, or the excretion of the substance became pathological when the metastases were already conspicuous. "
12/01/1980 - "When the disease became generalized, an increase of the urinary excretion of 5-S-Cysteinyldopa prior to the clinical manifestation of the metastases was observed in only four out of 26 cases. "
10/01/1993 - "Changes in plasma 5-S-cysteinyldopa concentration in B16 melanoma-bearing mice treated with interferon-beta or dacarbazine."
11/15/1997 - "The melanin metabolite 5-S-cysteinyldopa (5-S-CD) has been reported to be helpful in detecting occult melanoma metastases and as a prognostic marker in B16 melanoma-bearing mice. "
07/01/1994 - "The 5-S-cysteinyldopa level in sera of tumor-bearing mice correlated well with the size of the tumor. "
11/01/1992 - "5-S-cysteinyldopa in urine and tumors."
09/01/1990 - "Initially, the urinary excretion level of 5-S-cysteinyldopa (5-S-CD) was high, but, after resection of the tumor, the level of 5-S-CD returned to normal."
05/01/1984 - "Cell lines were initiated from primary or metastatic tumors and presented various levels of tumorigenicity (assessed by heterotransplantation in nude mice) and pigmentation (shown by 5-S-cysteinyldopa determination and cytological data). "
01/15/1980 - "In the palliatively treated patients, 5-S-cysteinyldopa excretion increased in 5/6 patients judged to have stable disease, before tumor progression was clinically detectable. "
|5.||Psoriasis (Pustulosis Palmaris et Plantaris)
03/01/2011 - "Increased cysteinyldopa plasma levels hint to melanocyte as stress sensor in psoriasis."
01/01/1983 - "Observations on PUVA treatment of psoriasis and on 5-S-cysteinyldopa after exposure to UV light."
01/01/1981 - "During PUVA treatment of 3 patients with psoriasis confined to the palms and/or soles a delayed increase in serum 5-S-Cysteinyldopa was noted after 5 weeks. "
11/01/2008 - "Serum 5-S-cysteinyldopa levels in patients with psoriasis undergoing narrowband ultraviolet B phototherapy."
03/01/2011 - "Aim of the present study was to assess whether plasma levels of 5-S-cysteinyldopa (CD), a metabolite reflecting melanocyte activity, undergo changes in association with psoriasis together with those of typical lipid peroxidation markers thiobarbituric acid reactive substances (TBARS). "
|3.||DNA (Deoxyribonucleic Acid)
|4.||Biological Markers (Surrogate Marker)
|9.||N-Acetylneuraminic Acid (Sialic Acid)
|10.||S-100 calcium-binding protein beta subunit
|1.||Combination Drug Therapy (Combination Chemotherapy)
|2.||Drug Therapy (Chemotherapy)
|4.||Phototherapy (Light Therapy)